152 related articles for article (PubMed ID: 38690600)
1. Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance.
Llinas-Bertran A; Bellet-Ezquerra M; Seoane JA
Cancer Discov; 2024 May; 14(5):704-706. PubMed ID: 38690600
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic Control of Cancer Cell Dormancy and Awakening in Endocrine Therapy Resistance.
Llinas-Bertran A; Bellet-Ezquerra M; Seoane JA
Cancer Discov; 2024 Apr; ():OF1-OF3. PubMed ID: 38598672
[TBL] [Abstract][Full Text] [Related]
3. Endocrine resistance in breast cancer: from cellular signaling pathways to epigenetic mechanisms.
Bianco S; Gévry N
Transcription; 2012; 3(4):165-70. PubMed ID: 22771991
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response.
Pathiraja TN; Stearns V; Oesterreich S
J Mammary Gland Biol Neoplasia; 2010 Mar; 15(1):35-47. PubMed ID: 20101445
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic mechanisms in breast cancer therapy and resistance.
Garcia-Martinez L; Zhang Y; Nakata Y; Chan HL; Morey L
Nat Commun; 2021 Mar; 12(1):1786. PubMed ID: 33741974
[TBL] [Abstract][Full Text] [Related]
6. Tamoxifen resistance and epigenetic modifications in breast cancer cell lines.
Badia E; Oliva J; Balaguer P; Cavaillès V
Curr Med Chem; 2007; 14(28):3035-45. PubMed ID: 18220739
[TBL] [Abstract][Full Text] [Related]
7. Reversal of endocrine resistance in breast cancer: interrelationships among 14-3-3ζ, FOXM1, and a gene signature associated with mitosis.
Bergamaschi A; Christensen BL; Katzenellenbogen BS
Breast Cancer Res; 2011 Jun; 13(3):R70. PubMed ID: 21707964
[TBL] [Abstract][Full Text] [Related]
8. Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer.
Giannoudis A; Malki MI; Rudraraju B; Mohhamed H; Menon S; Liloglou T; Ali S; Carroll JS; Palmieri C
Breast Cancer Res; 2020 Nov; 22(1):126. PubMed ID: 33198803
[TBL] [Abstract][Full Text] [Related]
9. Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer.
Soleimani Dodaran M; Borgoni S; Sofyalı E; Verschure PJ; Wiemann S; Moerland PD; van Kampen AHC
BMC Cancer; 2020 Jul; 20(1):676. PubMed ID: 32684154
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer.
Simigdala N; Gao Q; Pancholi S; Roberg-Larsen H; Zvelebil M; Ribas R; Folkerd E; Thompson A; Bhamra A; Dowsett M; Martin LA
Breast Cancer Res; 2016 Jun; 18(1):58. PubMed ID: 27246191
[TBL] [Abstract][Full Text] [Related]
11. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
12. Co-Expression Effect of SLC7A5/SLC3A2 to Predict Response to Endocrine Therapy in Oestrogen-Receptor-Positive Breast Cancer.
Alfarsi LH; El-Ansari R; Craze ML; Masisi BK; Mohammed OJ; Ellis IO; Rakha EA; Green AR
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093034
[TBL] [Abstract][Full Text] [Related]
13. Hormonal modulation in the treatment of breast cancer.
Adelson K; Germain D; Raptis G; Biran N
Endocrinol Metab Clin North Am; 2011 Sep; 40(3):519-32, viii. PubMed ID: 21889718
[TBL] [Abstract][Full Text] [Related]
14. Overcoming Endocrine Resistance in Breast Cancer.
Hanker AB; Sudhan DR; Arteaga CL
Cancer Cell; 2020 Apr; 37(4):496-513. PubMed ID: 32289273
[TBL] [Abstract][Full Text] [Related]
15. Aberrant Regulation of RAD51 Promotes Resistance of Neoadjuvant Endocrine Therapy in ER-positive Breast Cancer.
Jia Y; Song Y; Dong G; Hao C; Zhao W; Li S; Tong Z
Sci Rep; 2019 Sep; 9(1):12939. PubMed ID: 31506496
[TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.
Zilli M; Grassadonia A; Tinari N; Di Giacobbe A; Gildetti S; Giampietro J; Natoli C; Iacobelli S;
Biochim Biophys Acta; 2009 Jan; 1795(1):62-81. PubMed ID: 18804516
[TBL] [Abstract][Full Text] [Related]
17. Cancer stem-like properties of hormonal therapy-resistant breast cancer cells.
Uchiumi K; Tsuboi K; Sato N; Ito T; Hirakawa H; Niwa T; Yamaguchi Y; Hayashi SI
Breast Cancer; 2019 Jul; 26(4):459-470. PubMed ID: 30610551
[TBL] [Abstract][Full Text] [Related]
18. Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance.
Takahashi M; Hayashida T; Okazaki H; Miyao K; Jinno H; Kitagawa Y
Cancer Sci; 2014 Jun; 105(6):675-82. PubMed ID: 24698107
[TBL] [Abstract][Full Text] [Related]
19. The interaction between ER and NFκB in resistance to endocrine therapy.
Sas L; Lardon F; Vermeulen PB; Hauspy J; Van Dam P; Pauwels P; Dirix LY; Van Laere SJ
Breast Cancer Res; 2012 Aug; 14(4):212. PubMed ID: 22963717
[TBL] [Abstract][Full Text] [Related]
20. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
